Search hospitals > Kansas > Newton

Cancer Center of Kansas - Newton

Claim this profile
Newton, Kansas 67114
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
387 reported clinical trials
9 medical researchers
Photo of Cancer Center of Kansas - Newton in NewtonPhoto of Cancer Center of Kansas - Newton in Newton

Summary

Cancer Center of Kansas - Newton is a medical facility located in Newton, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Cancer Center of Kansas - Newton is involved with conducting 387 clinical trials across 454 conditions. There are 9 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Eric Whitman, MD, Charles M Farber, MD, and Dennis F. Moore.

Area of expertise

1Cancer
Global Leader
Cancer Center of Kansas - Newton has run 92 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Cancer Center of Kansas - Newton has run 85 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive

Top PIs

Clinical Trials running at Cancer Center of Kansas - Newton

Breast Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Bladder Cancer
Renal Cell Carcinoma
Cancer
Follicular Lymphoma
Squamous Cell Carcinoma
Tumors
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer Center of Kansas - Newton?
Cancer Center of Kansas - Newton is a medical facility located in Newton, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Cancer Center of Kansas - Newton is involved with conducting 387 clinical trials across 454 conditions. There are 9 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Eric Whitman, MD, Charles M Farber, MD, and Dennis F. Moore.
Where is Cancer Center of Kansas - Newton located?
The Cancer Center of Kansas, Newton, is located at 720 Medical Center Drive, Newton, KS 67114.
Who should I call to ask about financial aid or insurance network?
To contact the Cancer Center of Kansas - Newton, call (316) 262-4467 or visit <https://cancercenterofkansas.com>. For appointments, use the same number. For patient portal access, dial 316-262-4467 and enter extension 6161 upon hearing the recording. Specific contact details for each location are available on their website.
What insurance does Cancer Center of Kansas - Newton accept?
The Cancer Center of Kansas - Newton accepts a wide range of insurances, including Original Medicare (Parts A & B), Medicare Advantage (Part C) HMO plans, and commercial insurance plans such as Aetna Commercial, BCBS Commercial, Cigna, and Humana Commercial. It is important to verify with your insurance company that the Cancer Center of Kansas - Newton is in-network for your specific plan.
What awards or recognition has Cancer Center of Kansas - Newton received?
The Cancer Center of Kansas, located in Newton, Kansas, is renowned for its high-quality and innovative cancer care. It is part of a distinguished network that was named the Favorite Cancer Center of Kansas in the Wichita Kansas Reader's Choice Awards in 2016 and 2018. This network is also recognized for establishing the first community-based nationally recognized research program in 1983 through the National Cancer Institute (NCI).